An 18-year-old female dies from a blood clot two weeks after having her Covid vaccination.

An 18-year-old female was admitted to a hospital after she was experiencing 'thunder-clap' headaches, the "worst headache" she had ever experienced, two weeks after receiving her first dose of AstraZeneca Covid vaccine. An inquest heard the headaches were the result of thrombosis in her sinus cavity. 

Because of her low platelet count, doctors initially ruled out a brain hemorrhage. She suffered all of the "common" side effects of the vaccine but hoped these would last approximately 12 to 18 hours, the inquest heard. But two weeks later she was "screaming in pain" with the "worst headache" she had ever experienced. Despite this, a CT scan was reported as "normal". Three days after her admission, she was administered a dose of platelets and her inquest heard that she began to rapidly deteriorate. She suffered from fits and was "not responding to seizure control", the inquest heard. She was then incubated and put on a ventilator where doctors performed another CT scan, now revealing the blood clot. Doctors decided that brain surgery would not be in Kasey's best interest and could result in "significant brain damage". After Kasey's condition did not improve the following day, sedative drugs were withdrawn so doctors could accurately assess her neurological state. She was found to be "brain stem dead" so mechanical ventilation was withdrawn and she died later that day. Vaccine-induced immune thrombotic thrombocytopenia (VITT) appeared to be a "key" factor in her death. 

Another later-published case of an 18-year old male who developed Level 1 TTS (probable VITT) eight days after immunization with the ChADOx1 nCOV-19 vaccine, had a favorable outcome since his blood tests revealed mild thrombocytopenia and he was treated symptomatically. He did not recover completely, however, and his case could be similar to Long VITT cases. His initial symptoms were worsening headaches, vomiting and hemiparesis. Amongst cases identified in the same database, ta 21-year-old woman recovered from Thrombocytopenia Syndrome (TTS) and a 22-year-old woman died – both vaccinated with Covishield vaccine.


REFERENCES

Student paramedic, 18, died of clot two weeks after having Covid vaccine (msn.com)

Aspiring South Yorkshire paramedic, 18, died after receiving AstraZeneca Covid vaccine, inquest told | The Star

Family of teenager who died after having AstraZeneca jab pay tribute to 'cheeky' daughter | Yorkshire Post

Yorkshire Teenager Tragically Died After Developing Blood Clot Caused by Covid “Vaccine” – The Expose (dailyexpose.uk)

'Healthy' teen died after suffering 'thunderclap headache' following AstraZeneca Covid jab - Mirror Online

Aspiring Yorkshire paramedic, 18, died after receiving AstraZeneca Covid vaccine, inquest told | Yorkshire Post

Jain N, Chaudhary P, Shrivastava A, Kaur T, Kaur S, Brar HS, Jindal R. Thrombosis with Thrombocytopenia Syndrome (TTS) After ChAdOx1 nCoV-19 Immunization: An Investigative Case Report. Am J Case Rep. 2023 Mar 18;24:e938878. doi: 10.12659/AJCR.938878. PMID: 36932639.

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis ...
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an incr...
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high ...
Read more